Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $9.8 million.

  • Collegium Pharmaceutical's Share-based Compensation rose 3408.5% to $9.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.7 million, marking a year-over-year increase of 2497.33%. This contributed to the annual value of $32.4 million for FY2024, which is 1939.86% up from last year.
  • Per Collegium Pharmaceutical's latest filing, its Share-based Compensation stood at $9.8 million for Q3 2025, which was up 3408.5% from $10.8 million recorded in Q2 2025.
  • Over the past 5 years, Collegium Pharmaceutical's Share-based Compensation peaked at $11.5 million during Q1 2025, and registered a low of $4.9 million during Q4 2021.
  • Its 5-year average for Share-based Compensation is $7.3 million, with a median of $7.0 million in 2023.
  • Per our database at Business Quant, Collegium Pharmaceutical's Share-based Compensation plummeted by 2090.18% in 2021 and then soared by 5416.72% in 2025.
  • Over the past 5 years, Collegium Pharmaceutical's Share-based Compensation (Quarter) stood at $4.9 million in 2021, then rose by 15.43% to $5.7 million in 2022, then increased by 23.49% to $7.0 million in 2023, then grew by 8.48% to $7.6 million in 2024, then increased by 29.16% to $9.8 million in 2025.
  • Its last three reported values are $9.8 million in Q3 2025, $10.8 million for Q2 2025, and $11.5 million during Q1 2025.